🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsRetatrutide & Triple AgonistsBeen on the reta waiting list for months - anyone heard anything?

Been on the reta waiting list for months - anyone heard anything?

rick_sfbay Thu, Apr 16, 2026 at 7:16 PM 23 replies 1,035 viewsPage 1 of 5
rick_sfbay
Member
289
1,234
Jan 2025
San Francisco, CA
Apr 16, 2026 at 7:16 PM#1

Sceptical rather than excited about the triple agonist, and I would like somebody to talk me out of the scepticism with data rather than enthusiasm.

What would genuinely help is knowing why adding glucagon agonism to an anti-obesity drug is not self-defeating, given that glucagon raises blood glucose.

Numbers rather than impressions, if you have them.

24 19mike_mealprep, NicoleRaleigh, james_edin and 21 others
Reply Quote Save Share Report
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Apr 16, 2026 at 7:28 PM#2

Answering the narrow version, because the broad one does not have a single answer. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.

Last edited: Apr 16, 2026 at 8:28 PM
23 18anna.melb_AU, mark_tokyo, hans_munich and 20 others
Reply Quote Save Share Report
denise_HTX
Member
145
678
Jan 2025
Houston, TX
Apr 16, 2026 at 7:40 PM#3
Dr.RaviCardio said:
The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either.

Agreeing with Dr.RaviCardio, and the qualification matters more than the agreement. The phase 2 numbers were about 24% mean weight loss at 48 weeks on the top dose, with the curve still descending at the end of the study. A curve that has not flattened is a real finding, but it also means the true plateau is unknown, and phase 2 populations are small and selected.

22 17JessicaH_TX, KevinCompounds, TirzTom and 19 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
ZaraB_AL
Member
456
1,678
Jan 2025
Alabama
Apr 16, 2026 at 7:52 PM#4
rick_sfbay said:
Sceptical rather than excited about the triple agonist, and I would like somebody to talk me out of the scepticism with data rather than enthusiasm.

This is my experience too, for whatever a second data point is worth. The detail I would add is minor and it is already implied above.

Last edited: Apr 16, 2026 at 8:52 PM
21 16TrialTracker_MD, JennaRN, LabKate and 18 others
Reply Quote Save Share Report
LindaRN_retired
Member
189
890
Dec 2024
Sarasota, FL
Apr 16, 2026 at 8:57 PM#5

Adding the clinical framing, because it changes how the question reads. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

Last edited: Apr 16, 2026 at 11:57 PM
20 15mike_nyc, VendorMark, COA_Karl and 17 others
Reply Quote Save Share Report
1235

Similar Threads

TRIUMPH-3 topline results — 24.2% body weight loss at 48 weeks10 replies
Retatrutide mechanism: GLP-1/GIP/glucagon triple agonism explained5 replies
Retatrutide Phase 2 dose-response analysis — optimal dose range10 replies
Glucagon receptor agonism and hepatic lipid oxidation — MASH implications13 replies
Retatrutide vs tirzepatide — dual vs triple agonist comparison22 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register